FY2025 EPS Estimates for Legend Biotech Decreased by Analyst

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) – Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Legend Biotech in a report issued on Thursday, November 13th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will post earnings of ($1.54) per share for the year, down from their previous forecast of ($1.48). Cantor Fitzgerald has a “Overweight” rating and a $75.00 price target on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share.

Legend Biotech (NASDAQ:LEGN) last announced its earnings results on Wednesday, November 12th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. The company had revenue of $272.33 million for the quarter, compared to the consensus estimate of $277.91 million. Legend Biotech had a negative return on equity of 24.47% and a negative net margin of 26.37%.The company’s revenue was up 70.0% on a year-over-year basis. During the same period last year, the business posted ($0.34) EPS.

Several other research firms have also recently issued reports on LEGN. Royal Bank Of Canada cut their price target on shares of Legend Biotech from $75.00 to $74.00 and set an “outperform” rating for the company in a report on Thursday, November 13th. Johnson Rice set a $60.00 price target on Legend Biotech in a research note on Friday, October 17th. JPMorgan Chase & Co. cut their price objective on Legend Biotech from $78.00 to $76.00 and set an “overweight” rating for the company in a research report on Thursday, October 9th. Barclays decreased their target price on shares of Legend Biotech from $94.00 to $90.00 and set an “overweight” rating on the stock in a research report on Thursday, November 13th. Finally, HC Wainwright lowered their price target on shares of Legend Biotech from $75.00 to $60.00 and set a “buy” rating on the stock in a research note on Friday, October 17th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $72.10.

Legend Biotech Stock Down 1.0%

LEGN stock opened at $29.42 on Monday. The stock has a market capitalization of $5.43 billion, a PE ratio of -45.26 and a beta of 0.17. The company has a fifty day moving average of $32.45 and a 200-day moving average of $34.26. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.80 and a current ratio of 2.86. Legend Biotech has a one year low of $27.34 and a one year high of $45.30.

Hedge Funds Weigh In On Legend Biotech

Several hedge funds have recently added to or reduced their stakes in the business. Clearstead Advisors LLC raised its position in Legend Biotech by 76.5% during the third quarter. Clearstead Advisors LLC now owns 847 shares of the company’s stock worth $28,000 after acquiring an additional 367 shares during the last quarter. Parallel Advisors LLC lifted its stake in Legend Biotech by 171.9% in the 3rd quarter. Parallel Advisors LLC now owns 1,047 shares of the company’s stock valued at $34,000 after buying an additional 662 shares in the last quarter. OFI Invest Asset Management grew its holdings in Legend Biotech by 102.6% during the 3rd quarter. OFI Invest Asset Management now owns 1,228 shares of the company’s stock valued at $40,000 after buying an additional 622 shares during the last quarter. Quarry LP acquired a new position in shares of Legend Biotech in the first quarter worth $48,000. Finally, Brooklyn Investment Group raised its holdings in shares of Legend Biotech by 1,114.8% in the first quarter. Brooklyn Investment Group now owns 1,725 shares of the company’s stock worth $59,000 after acquiring an additional 1,583 shares during the last quarter. 70.89% of the stock is currently owned by hedge funds and other institutional investors.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).